Fortis Healthcare reported robust financial performance for FY 2025-26 with revenue up 17.28% and profit surging 31.48%. The company also recommended a dividend and expanded its operations through acquisitions.
Fortis Healthcare Posts Strong FY26 Results Amid Expansion
Fortis Healthcare's revenue from operations for FY 2025-26 reached ₹9,127.84 crore, a 17.28% increase from ₹7,782.75 crore in the previous fiscal.
Profit for the year grew by 31.48% to ₹1,064.19 crore, up from ₹809.38 crore in FY 2024-25.
Reader Takeaway: Strong growth drivers offset by persistent regulatory concerns.
What just happened
Fortis Healthcare announced its financial results for the fiscal year 2025-26, reporting significant year-on-year growth in both revenue and profitability. Consolidated revenue from operations rose to ₹9,127.84 crore from ₹7,782.75 crore. The company's profit for the year saw a substantial jump of 31.48%, reaching ₹1,064.19 crore compared to ₹809.38 crore in the prior year. Earnings Per Share (EPS) improved to ₹13.80 from ₹10.26. The Board of Directors has recommended a final dividend of ₹1.00 per equity share, subject to shareholder approval.
Why this matters
These results indicate a strong operational performance and expanding business footprint for Fortis Healthcare. The revenue and profit growth demonstrate the company's ability to scale its services and improve efficiency. The recommended dividend signals confidence in sustained cash flows. Acquisitions and brand transition also point towards strategic growth initiatives.
The backstory
Fortis Healthcare has been actively pursuing a growth strategy, including inorganic expansion. The company recently acquired TMI Healthcare Private Limited (People Tree Hospital, Bengaluru) and the business operations of Shrimann Superspecialty Hospital, Jalandhar. The diagnostic business has undergone a brand transition to 'Agilus'. However, the company continues to face a regulatory overhang from investigations related to transactions from the time of its erstwhile promoters.
What changes now
With improved financial metrics and strategic acquisitions, Fortis Healthcare is positioned for continued growth. The successful brand transition in diagnostics is expected to streamline operations. Investors will be watching the company's ability to integrate acquisitions and manage the ongoing legal matters.
Risks to watch
The primary concern remains the ongoing regulatory investigations by the SFIO and EOW concerning past promoter-era transactions. While the management believes the likelihood of material financial impact is low, any adverse developments could affect the company's valuation and operations.
Peer comparison
(No specific peer comparison data was provided in the filing.)
Context metrics (time-bound)
- Revenue Growth (FY25-26 vs FY24-25): 17.28%
- Profit Growth (FY25-26 vs FY24-25): 31.48%
- EPS (FY25-26): ₹13.80
- EPS (FY24-25): ₹10.26
- Acquisition Dates: TMI Healthcare (Jan 9, 2026), Shrimann Superspecialty Hospital (July 24, 2025)
What to track next
Investors should monitor updates on the SFIO and EOW investigations. Further announcements on integration of acquired hospitals and performance of the 'Agilus' diagnostics brand will also be key indicators.